

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

09 Jul 2026

### Comparison of the effect of dialysates with 2meq/l and 3meq/l potassium as a result of adding KCl on serum potassium levels of patients before and after hemodialysis in hemodialysis patients

#### Protocol summary

dialysate potassium before and after dialysis

##### Study aim

Comparison of the effect of dialysates with 2meq/l potassium and 2meq/l potassium as a result of adding KCl on serum potassium levels of patients before and after hemodialysis in hemodialysis patients

##### Design

A clinical trial with a control group, based on the community, with parallel groups, with the blinding of the data analyst, randomized phase3, on 160 patients. For randomization, block randomization of four of the sites sealed envelope.com

##### Settings and conduct

First, the serum potassium of the patients will be measured. Then, the case group will undergo dialysis with 2meq/l potassium dialysate, to which 17.5 cc ampoules of potassium chloride 15% added to each liter. The control group will undergo dialysis with 2meq/l potassium dialysate. After the end of dialysis, the serum potassium of the patients will be measured once again immediately and once 6 hours after the end of dialysis. In this blinding study the person in charge of analyzing and analyzing the data will not be aware of the intervention received by each person. Hemodialysis Department of Khurshid Hospital, Isfahan September 2022

##### Participants/Inclusion and exclusion criteria

Age more than 20 years and less than 75 Have a regular treatment plan and undergo hemodialysis 3 times a week Have a serum potassium level of less than and equal to 4.5

##### Intervention groups

The group 1 will undergo dialysis with 2meq/l potassium dialysate, to which 17.5 cc ampoules of potassium chloride 15% have been added to each liter of concentrated dialysate. The group 2 will undergo dialysis with 2meq/l potassium dialysate.

##### Main outcome variables

patients serum potassium before and after dialysis

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20220703055361N1**

Registration date: **2023-02-19, 1401/11/30**

Registration timing: **retrospective**

Last update: **2023-02-19, 1401/11/30**

Update count: **0**

##### Registration date

2023-02-19, 1401/11/30

##### Registrant information

##### Name

Mehran Haddadi

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 81 3821 7276

##### Email address

haddadi.mehran@gmail.com

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2022-08-23, 1401/06/01

##### Expected recruitment end date

2022-10-23, 1401/08/01

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

## Trial completion date

empty

## Scientific title

Comparison of the effect of dialysates with 2meq/l and 3meq/l potassium as a result of adding KCl onserum potassium levels of patients before and after hemodialysis in hemodialysis patients

## Public title

Effect of Different dialysates on serum potassium

## Purpose

Treatment

## Inclusion/Exclusion criteria

### Inclusion criteria:

hemodialysis for more than 3 months stable physical and laboratory condition regular treatment program (3 times dialysis per week) stable vascular access stable blood pressure stable hemodynamic and cardiovascular condition serum potassium less than or equal to 4.5 The patient should be hospitalized. (for the convenience of measuring potassium 6 hours after the end of dialysis)

### Exclusion criteria:

need a blood transfusion for any reason

## Age

From **20 years** old to **75 years** old

## Gender

Both

## Phase

N/A

## Groups that have been masked

*No information*

## Sample size

Target sample size: **160**

## Randomization (investigator's opinion)

Randomized

## Randomization description

For this purpose, we will use the block randomization method. For this purpose, the website <https://www.sealedenvelope.com/> will be used. 40 blocks of 4 will be created by the site, which will assign 2 people to the Case group and 2 people to the Control group in each block.

## Blinding (investigator's opinion)

Not blinded

## Blinding description

## Placebo

Not used

## Assignment

Parallel

## Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

Name of ethics committee

Research Ethics Committees of Research Ethics Committee of the "Alzahra Research Centers"

## Street address

Address: Hazar Jarib St., Isfahan University of Medical Sciences and Health Care Services, Building No. 4 - University Research and Technology Vice-Chancellor

## City

اصفهان

## Province

Isfahan

## Postal code

۷۳۴۶۱۸۱۷۴۶

## Approval date

2022-04-20, 1401/01/31

## Ethics committee reference number

IR.ARI.MUI.REC.1401.027

## Health conditions studied

### 1

#### Description of health condition studied

hyperkalemia in hemodialysis patients

#### ICD-10 code

N18.5

#### ICD-10 code description

Chronic kidney disease, stage 5

## Primary outcomes

### 1

#### Description

serum potassium level

#### Timepoint

Measurement of serum potassium in patients before dialysis, immediately after dialysis, 6 hours after dialysis

#### Method of measurement

Serum potassium measurement of patients in the laboratory by electrode method and using EasyLyte REF 2124 device

### 2

#### Description

dialysate potassium level

#### Timepoint

Measurement of potassium level of dialysate during dialysis from afferent and efferent coupling

#### Method of measurement

dialysate potassium measurement in the laboratory by electrode method and using EasyLyte REF 2124 device

## Secondary outcomes

empty

## Intervention groups

### 1

#### Description

Intervention group: Dialysis with 2 meq/l potassium dialysate to which 17.5 cc ampoules of 15% potassium chloride have been added per liter of concentrated dialysis solution (equivalent to 3 meq/l solution)

**Category**

Treatment - Other

**2**

**Description**

Control group: Dialysis with 2 meq/l potassium dialysate

**Category**

Treatment - Other

**Recruitment centers**

**1**

**Recruitment center**

**Name of recruitment center**

khoshid medical educational research complex

**Full name of responsible person**

Abdolamir Atapour

**Street address**

No. 105, Ostandari Street, Isfahan, Isfahan Province

**City**

Isfahan

**Province**

Hamadan

**Postal code**

8145833117

**Phone**

+98 31 3222 2127

**Email**

nour@mui.ac.ir

**Sponsors / Funding sources**

**1**

**Sponsor**

**Name of organization / entity**

Esfahan University of Medical Sciences

**Full name of responsible person**

Dr gholamreza Asgari

**Street address**

building no.4, isfahan university of medical sciences,  
hezar jirib street, isfahan

**City**

isfahan

**Province**

Isfahan

**Postal code**

817467346

**Phone**

+98 31 3668 8138

**Email**

research@mui.ac.ir

**Grant name**

**Grant code / Reference number**

**Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Esfahan University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

empty

**Country of origin**

**Type of organization providing the funding**

Academic

**Person responsible for general inquiries**

**Contact**

**Name of organization / entity**

Esfahan University of Medical Sciences

**Full name of responsible person**

Mehran Haddadi

**Position**

Student

**Latest degree**

A Level or less

**Other areas of specialty/work**

General Practitioner

**Street address**

Arjan apartment, kouchmeshki st, fatemieh blvd,

**City**

Hamadan

**Province**

Hamadan

**Postal code**

6515913463

**Phone**

+98 81 3821 7276

**Fax**

**Email**

Haddadi.mehran@gmail.com

**Person responsible for scientific inquiries**

**Contact**

**Name of organization / entity**

Esfahan University of Medical Sciences

**Full name of responsible person**

Mehran Haddadi

**Position**

general medicine student

**Latest degree**

A Level or less

**Other areas of specialty/work**

Internal Medicine

**Street address**

No. 1, Arjan apartment, koochmeshki Ave., Fatemieh Blvd., hamedan Town

**City**

hamedan

**Province**

Hamadan  
**Postal code**  
6515913463  
**Phone**  
+98 81 3821 7276  
**Email**  
haddadi.mehran@gmail.com

6515913463  
**Phone**  
+98 81 3821 7276  
**Email**  
haddadi.mehran@gmail.com

## Person responsible for updating data

### Contact

**Name of organization / entity**  
Esfahan University of Medical Sciences  
**Full name of responsible person**  
Mehran Haddadi  
**Position**  
general medicine student  
**Latest degree**  
A Level or less  
**Other areas of specialty/work**  
Internal Medicine  
**Street address**  
No. 1, Arjan apartment, koochmeshki Ave., Fatemieh  
Blvd., hamedan Town  
**City**  
همدان  
**Province**  
Hamadan  
**Postal code**

## Sharing plan

### Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

### Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

### Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

### Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

### Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

### Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

### Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available